Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab with radiotherapy, with or without nivolumab, for metastatic melanoma
ACTRN12613000385741Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab and nivolumab in melanoma (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Toxicity profile, Tumor response by RECIST 1.1 and 1 more. Started Sep 2014; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12613000385741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000385741.